Turalio
Payments companies reported to CMS as associated with Turalio. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Turalio, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Turalio
These are the largest totals companies reported as associated with Turalio. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Kamalesh Sankhala | Beverly Hills, CA | Medical Oncology | $35,647.71 |
| Arun Singh | Santa Monica, CA | Hematology & Oncology | $34,704.86 |
| Shreyaskumar Patel | Houston, TX | Medical Oncology | $30,349.22 |
| Thomas Scharschmidt | Columbus, OH | Orthopaedic Surgery | $23,522.22 |
| Francis Hornicek | Miami, FL | Orthopaedic Surgery | $23,191.81 |
| Vinod Ravi | Houston, TX | Medical Oncology | $23,090.26 |
| Brian Van Tine | Saint Peters, MO | Medical Oncology | $15,599.79 |
| Nicholas Bernthal | Venice, CA | Orthopaedic Surgery | $14,876.39 |
| William Tap | New York, NY | Hematology & Oncology | $14,305.84 |
| Atrayee Basu Mallick | Philadelphia, PA | Hematology & Oncology | $14,210.63 |
Prescribed Turalio?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.